Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia
A blood test that detects cancer DNA fragments predicts which leukemia patients will relapse far better than current methods, potentially sparing some from unnecessary treatment.
Personalized plasma ctDNA profiling (AML-CAPP-Seq) using whole-exome-informed variant panels universally detected MRD in 56 AML patients, outperforming cellular MRD with HR 17.8 for relapse-free survival and achieving HR 36.0 (p=0.0009) for relapse prediction in 29 allogeneic transplant recipients. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- prospective_cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Blood Cancer Discovery
Why it surfaced
High-impact translational study from Stanford demonstrating a universal, highly sensitive ctDNA MRD platform for AML. Peri-transplant HR of 36.0 for relapse prediction far exceeds current standard-of-care; directly addresses the critical unmet need for sensitive MRD surveillance across diverse AML subtypes. Published in Blood Cancer Discovery.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.